SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Biopharma Update on the Novel Coronavirus: May 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 29, 2020.
May 28, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Neurotrope and NIH Launch Long-Term Trial of Bryostatin in Alzheimer’s
The Phase II study will be performed in collaboration with the National Institutes of Health under a $2.7 million grant.
May 28, 2020
 · 
2 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
May 28, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
May 27, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
CEPI-Backed Novavax Doses First Patients with COVID-19 Vaccine Candidate
The Maryland-based company has enrolled and dosed its first patients in a Phase I/II study.
May 26, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: May 26
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
May 26, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
CanSino Publishes Phase I Data for COVID-19 Vaccine Candidate, Moves into Phase II
A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting its safety in patients.
May 22, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biotech Bay Companies Fighting Against COVID-19
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
May 22, 2020
 · 
11 min read
 · 
Chelsea Weidman Burke, M.S.
BioForest
Clinical Catch-Up: May 18-22
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
May 22, 2020
 · 
9 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
May 22, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Drug Development
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
February 24, 2024
 · 
8 min read
Drug Development
Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
February 22, 2024
 · 
3 min read
Drug Development
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
February 22, 2024
 · 
4 min read
Drug Development
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
February 22, 2024
 · 
5 min read
Drug Development
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
February 22, 2024
 · 
6 min read
Drug Development
Ashvattha Therapeutics Announces First Patient Enrolled in Expanded Phase 1/2 Study of Imaging Agent 18F-OP-801 in Additional Neurological Indications
February 22, 2024
 · 
3 min read
Drug Development
CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D)
February 22, 2024
 · 
3 min read
Drug Development
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
February 22, 2024
 · 
6 min read
Drug Development
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
February 22, 2024
 · 
8 min read
Drug Development
OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program
February 22, 2024
 · 
6 min read
Drug Development
Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn’s and Colitis Organisation (ECCO)
February 22, 2024
 · 
4 min read
Drug Development
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
February 22, 2024
 · 
7 min read
Drug Development
LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V
February 22, 2024
 · 
4 min read
Drug Development
IRLAB has Completed a Successful End-of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam
February 22, 2024
 · 
4 min read
Drug Development
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
February 21, 2024
 · 
9 min read
Drug Development
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
February 21, 2024
 · 
7 min read
Drug Development
ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
February 21, 2024
 · 
3 min read
Drug Development
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
February 21, 2024
 · 
3 min read
Drug Development
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
February 21, 2024
 · 
9 min read
Drug Development
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
February 21, 2024
 · 
6 min read
Load More